GSK's Licensor Delivers First-Ever Positive Phase III Survival Data for B7-H3 ADC Ris-Rez in Lung Cancer
GSK sits 49% above its 52-week low of $35.45.
Summary
GSK's licensor Hansoh Pharma announced that the phase III ARTEMIS-008 trial of Ris-Rez met its primary endpoint of overall survival in advanced small-cell lung cancer—the first positive phase III OS data for a B7-H3-targeted ADC. The results will support regulatory submission in China and validate GSK's global development program.
Key Events · Product Development and Regulatory · GSK
-
Positive Phase III OS Data
The ARTEMIS-008 trial in China met its primary endpoint of overall survival in advanced/relapsed SCLC, demonstrating a statistically significant and clinically meaningful improvement versus topotecan.
-
First-in-Class Validation
These are the first positive phase III overall survival data for any B7-H3-targeted ADC, validating the target and de-risking GSK's global Ris-Rez program.
-
Regulatory Path in China
Hansoh Pharma will use the data for regulatory submission in China, potentially bringing a new treatment option to a population with high unmet need.
-
Global Pivotal Data Expected Next Year
GSK's global phase III EMBOLD SCLC-301 trial in relapsed ES-SCLC is ongoing, with pivotal data expected next year, which could support approvals outside China.
Analysis · GSK · Life Sciences
Hansoh Pharma's ARTEMIS-008 trial in China met its primary endpoint of overall survival in advanced small-cell lung cancer, marking the first positive phase III OS data for any B7-H3-targeted ADC. This outcome validates the mechanism and de-risks GSK's global development program, which includes the pivotal EMBOLD SCLC-301 trial with data expected next year. The results strengthen the case for regulatory submissions in China and support GSK's broader oncology ambitions across multiple solid tumors.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $52.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.2B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.